Watchlist Price Alert

Janux Therapeutics Inc. (JANX)

NASDAQ: JANX · Real-Time Price · USD

23.91

-1.31 (-5.19%)

At close: May 27, 2025, 3:32 PM

-5.19% (1D)

Bid	23.82
Market Cap	1.41B
Revenue (ttm)	9.34M
Net Income (ttm)	-77.74M
EPS (ttm)	-1.36
PE Ratio (ttm)	-17.58
Forward PE	-9.92
Analyst	Buy

Ask	24
Volume	740,290
Avg. Volume (20D)	1,000,790
Open	25.30
Previous Close	25.22
Day's Range	23.52 - 25.44
52-Week Range	22.48 - 71.71
Beta	3.24

About JANX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol JANX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for JANX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

5 months ago

+11.64%

Janux Therapeutics shares are trading higher after... Unlock content with Pro Subscription

5 months ago

+48.98%

Janux Therapeutics shares are trading higher after the company announced updated interim clinical data for its JANX007 program in prostate cancer.

News

1 week ago · businesswire.com

Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its p...

3 weeks ago · businesswire.com

Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates.

1 month ago · seekingalpha.com

Janux Therapeutics: Buying For The Promising Pipeline, Holding For The Buyout

Janux Therapeutics' lead program, JANX007, shows promising early results in prostate cancer, with significant PSA declines and no serious side effects reported. The company's strong financial position...

2 months ago · 247wallst.com

Insiders Are Loading Up on These 4 Biotech Stocks Now

Things are heating up in the biotechnology space, with a flurry of recent initial public offerings and some notable insider purchases of the past week or so.